113 filings
Page 4 of 6
DEF 14A
cbfvk16
15 Jun 22
Definitive proxy
5:01pm
8-K
3thcsn813ehj5
16 May 22
Virpax Pharmaceuticals Reports 2022 First Quarter Results and Recent Developments
9:10am
S-8
8m1c1
6 May 22
Registration of securities for employees
5:00pm
8-K
askhy
31 Mar 22
Virpax Pharmaceuticals Reports 2021 Year-End Results
9:05am
8-K
gu3gw7 nafgx
15 Mar 22
Virpax Pharmaceuticals Expands AnQlarâ„¢ Development and Commercialization Rights Through Worldwide Licensing Agreement
4:30pm
8-K
mdu7 hxncc0gg
15 Nov 21
Virpax Pharmaceuticals Reports 2021 Third Quarter Results and Recent Developments
12:00am
POS EX
6pknkl18y7s8k28 9s
15 Sep 21
Additional exhibits for listing
4:31pm
424B4
lr8s5 rt8k9rm
15 Sep 21
Prospectus supplement with pricing info
4:31pm
EFFECT
5ui0xpp3rq0xd6pq0
15 Sep 21
Notice of effectiveness
12:16am
FWP
5p32g4
10 Sep 21
Free writing prospectus
12:00am
CORRESP
j2kpw
9 Sep 21
Correspondence with SEC
12:00am
CORRESP
hf6 e336futnuuv
9 Sep 21
Correspondence with SEC
12:00am
UPLOAD
sti6figl
9 Sep 21
Letter from SEC
12:00am
DRS
v4ui3a9l 2k2
1 Sep 21
Draft registration statement
12:00am
8-K
0tlk34opcm1z
10 Aug 21
Virpax Pharmaceuticals Reports 2021 Second Quarter Results and Recent Developments
9:05am